BofA Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE): "current valuation undervalues the pipeline opportunity"
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $51.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
